Ambrisentan: A guide to its use in pulmonary arterial hypertension classified as WHO functional class II or III

[21] Waxman A.B., A short-term delay of endothelin receptor antagonist therapy results in a decreased long-term improvement in exercise capacity [abstract], 75th Annual Meeting of the American College of Chest Physicians, (2009)

[22] Keogh A., Ambrisentan therapy for idiopathic pulmonary arterial hypertension: 2 year follow-up [abstract no. 685], J Heart Lung Transplant, 28, 2 SUPPL., (2009)

[23] Badesch D., Ambrisentan therapy for pulmonary arterial hypertension associated with connective tissue diseases [abstract no. 2166], 71st Annual Scientific Meeting of the American College of Rheumatology and the 42nd Annual Meeting of the Association of Rheumatology Health Professionals, (2007)

[24] Pulido T., Long-term ambrisentan therapy for pulmonary arterial hypertension: Comparison by etiology [abstract], Am J Respir Crit Care Med, 179, (2009)

[25] Badesch D.B., Feldman J., Keogh A., Et al., ARIES 3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension [abstract], Am J Respir Crit Care Med, 179, (2009)

[26] Rowan C.A., Lederer D., Lee K.S., Et al., Ambrisentan: Safety and efficacy in the treatment of Eisenmenger syndrome [abstract], Am J Respir Crit Care Med, 179, (2009)

[27] Cartin-Ceba R., Swanson K., Iyer V., Et al., Safety and efficacy of ambrisentan for the therapy of portopulmonary hypertension, Chest

[28] Scott R.L., Steidley D.E., Gopalan R.S., Et al., Efficacy of Ambrisentan in Treatment of Porto-pulmonary Hypertension in Patients with End-stage Liver Disease [Abstract] 2010 American Transplant Congress, (2010)

[29] Ivy D., Rosenzwieg E.B., Calderbank M., Et al., Pharmacokinetics and safety of ambrisentan in pediatric patients with pulmonary arterial hypertension [abstract], Am J Respir Crit Care Med, 181, (2010)

[30] Torres F., Ambrisentan two-year results in patients with pulmonary arterial hypertension: An analysis of monotherapy and combination therapy [abstract], 75th Annual Meeting of the American College of Chest Physicians, (2009)

[21] Waxman A.B., A short-term delay of endothelin receptor antagonist therapy results in a decreased long-term improvement in exercise capacity [abstract], 75th Annual Meeting of the American College of Chest Physicians, (2009)

[22] Keogh A., Ambrisentan therapy for idiopathic pulmonary arterial hypertension: 2 year follow-up [abstract no. 685], J Heart Lung Transplant, 28, 2 SUPPL., (2009)

[23] Badesch D., Ambrisentan therapy for pulmonary arterial hypertension associated with connective tissue diseases [abstract no. 2166], 71st Annual Scientific Meeting of the American College of Rheumatology and the 42nd Annual Meeting of the Association of Rheumatology Health Professionals, (2007)

[24] Pulido T., Long-term ambrisentan therapy for pulmonary arterial hypertension: Comparison by etiology [abstract], Am J Respir Crit Care Med, 179, (2009)

[25] Badesch D.B., Feldman J., Keogh A., Et al., ARIES 3: Ambrisentan therapy in a diverse population of patients with pulmonary hypertension [abstract], Am J Respir Crit Care Med, 179, (2009)

[26] Rowan C.A., Lederer D., Lee K.S., Et al., Ambrisentan: Safety and efficacy in the treatment of Eisenmenger syndrome [abstract], Am J Respir Crit Care Med, 179, (2009)

[27] Cartin-Ceba R., Swanson K., Iyer V., Et al., Safety and efficacy of ambrisentan for the therapy of portopulmonary hypertension, Chest

[28] Scott R.L., Steidley D.E., Gopalan R.S., Et al., Efficacy of Ambrisentan in Treatment of Porto-pulmonary Hypertension in Patients with End-stage Liver Disease [Abstract] 2010 American Transplant Congress, (2010)

[29] Ivy D., Rosenzwieg E.B., Calderbank M., Et al., Pharmacokinetics and safety of ambrisentan in pediatric patients with pulmonary arterial hypertension [abstract], Am J Respir Crit Care Med, 181, (2010)

[30] Torres F., Ambrisentan two-year results in patients with pulmonary arterial hypertension: An analysis of monotherapy and combination therapy [abstract], 75th Annual Meeting of the American College of Chest Physicians, (2009)